Breaks Categories: News

ThursdaySep 12, 2024 2:08 pm

HempNewsBreaks – CannabisNewsWire and IBN Partner with NY Cannabis Insider to Boost Visibility for Premier Cannabis Event

CannabisNewsWire (“CNW”), a specialized communications platform for the cannabis sector and one of the 65+ brands powered by IBN, on Thursday announced that it has been named the Official NewsWire of the NY Cannabis Insider event, with IBN serving as the Official Media Sponsor. The event, scheduled for September 25, 2024, at The Desmond Hotel in Albany, NY, will focus on "Making Money in the Legal NYS Market," featuring industry leaders sharing insights on building profitable cannabis businesses. CNW will amplify the event’s coverage through its vast syndication network, while IBN will drive visibility across its family of brands. This…

Continue Reading

ThursdaySep 12, 2024 12:05 pm

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Partnership to Boost Operational Capacity, Sustain Revenue Growth in Logistics Division

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced a strategic partnership between LE Logistics, LLC, its wholly owned subsidiary, and West End Trucking, Inc. The partnership is expected to significantly boost the company’s asset base and operational capacity and set the stage for continued revenue growth and long-term success. Under the partnership, LE Logistics will manage and operate a fleet of 13 trucks and trailers under its own and West End’s licenses. Specifically, LE Logistics will handle all day-to-day logistics operations and create a robust system for fleet management, while West End will ensure compliance with all…

Continue Reading

ThursdaySep 05, 2024 11:16 am

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher is a recognized industry veteran with over three decades of experience in the medical device and pharmaceutical industries. He has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets. Mr. Christopher takes over from outgoing CEO, Chris Bunka, who has stepped aside from the role. Mr. Bunka remains as the Chairman of the Board of Directors and has been appointed Executive Strategic Advisor to the…

Continue Reading

TuesdaySep 03, 2024 12:24 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has entered into a Materials Transfer Agreement with a pharmaceutical company. Under the terms of the agreement, the pharmaceutical company will evaluate Lexaria’s DehydraTECH(TM) technology in a pre-clinical setting. Lexaria will be responsible for formulating and supplying certain DehydraTECH compositions, with the pharmaceutical company evaluating the pharmacokinetics of these compositions in animal studies. According to the company, Lexaria has awarded the pharmaceutical company a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination. The work is expected to be completed within roughly 6 months…

Continue Reading

ThursdayAug 29, 2024 12:13 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the tolerability and additional pharmacokinetic (“PK”) results from its human pilot study #2, GLP-1-H24-2, have been received. According to the results, absorption improvements appear to continue with DehydraTECH-processed Rybelsus(R) vs. Rybelsus tablets, even under “fed” conditions. The results also show that DehydraTECH-treated Rybelsus does absorb through a mouth-melt product format. “We were pleased to find that none of the nine people taking the DehydraTECH-processed Rybelsus swallowed as a capsule experienced any adverse events whatsoever,” the company stated in the press release. “However, of the nine human…

Continue Reading

ThursdayAug 22, 2024 10:22 am

HempNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Subsidiary Secures Motor Carrier Authority, DOT Licenses

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced that its wholly owned subsidiary, LE Logistics, LLC (LE”), has officially secured the Motor Carrier Authority (“MC”) and U.S. Department of Transport (“DOT”) licenses. This development positions LE to immediately launch its freight division under the Golden Triangle Ventures umbrella and sets the stage for a stronger and more compliant operational foundation. In addition, it positions LE to start operations with its initial fleet of assets under a brand-new, clean operating license. The licenses also prime LE to execute its strategy of operating a larger fleet of assets, driving…

Continue Reading

WednesdayAug 21, 2024 12:39 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes Control

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced receipt of blood glucose results from weeks 4 and 8 of its ongoing animal study WEIGHT-A24-1. The study is underway using diabetic, pre-conditioned Zucker rats. The results showed that DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A and B) were the top performers in the study at day 56, reducing blood sugar levels by 2.50%, 1.90% and 1.53% respectively. These results appear to support Lexaria’s belief that DehydraTECH-CBD may have utility, particularly if used together with a GLP-1 drug, in diabetic control. Additionally, select DehydraTECH-CBD…

Continue Reading

WednesdayAug 21, 2024 11:23 am

HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Three U.S. Patent Issuances

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates, today announced its receipt of three patents granted in the U.S., strengthening its patent portfolio. The issued patents include one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation. As of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use. “We are pleased to…

Continue Reading

MondayAug 19, 2024 11:48 am

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has released a report noting the positive findings from its applied research program. The program, which evaluated important mode of action facets of DehydraTECH(TM) processed with semaglutide, the glucagon-peptide 1 (“GLP-1”) drug, was conducted with the National Research Council of Canada ("NRC"). According to the company, the program was designed to examine the molecular properties of DehydraTECH-processed pure semaglutide in comparison to the commercially available semaglutide formulation Rybelsus(R). The program used simulated gastric fluid in order to mimic conditions in the human gut. Several testing methods were used, including…

Continue Reading

ThursdayAug 15, 2024 11:39 am

HempNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Reports on Voting Results of 2024 Annual and Special Meeting of Shareholders

Flora Growth (NASDAQ: FLGC), a consumer-packaged goods leader and pharmaceutical distributor, is reporting on its 2024 Annual and Special Meeting of Shareholders. The meeting. According to the announcement, shareholders voted on and approved all five proposals on the agenda. Proposals included the election of four directors to the company’s board of directors; the reappointment of Davidson & Company LLP, an independent registered public accounting firm, as the company auditors; amending FLGC’s Incentive Compensation Plan to increase the issuable number of shares; granting stock appreciation rights to the company's CEO and CFO; and issuing 635,363 shares in accordance with NASDAQ guidelines…

Continue Reading